RXRX

Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock?

Recursion Pharmaceuticals is expanding its clinical pipeline across oncology and rare diseases, with REC-4881 and multiple programs offering potential growth catalysts.

RXRX, SDGR, RLAY and ABSI are using AI-powered platforms to transform drug discovery while advancing proprietary clinical pipelines.

Recursion Pharmaceuticals NASDAQ: RXRX is using artificial intelligence to generate and analyze biological data in an effort to improve drug discovery, advance internal therapeutic programs and support collaborations with larger pharmaceutical companies, CFO and President of Recursion U.K. Ben Taylor said during a BofA Global Research virtual conference.

Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America SMID Cap Virtual Conference Transcript

Recursion misses Q2 earnings and revenue estimates as collaboration revenues fall year over year, sending shares lower while pipeline and partnership programs advanced.

Recursion Pharmaceuticals NASDAQ: RXRX outlined progress across its clinical pipeline, drug-discovery partnerships and AI-enabled research platform, while lowering its 2026 cash operating expense guidance to $375 million and reaffirming expectations for an operating runway through early 2028.

Recursion Pharmaceuticals, Inc. (RXRX) Q2 2026 Earnings Call Transcript

Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.41 per share a year ago.

Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated targets for drug discovery REC-4881 (MEK1/2 inhibitor): Additional Phase 2 data in Familial Adenomatous Polyposis (FAP) to be presented at the Presidential Plenary session at leading hereditary GI annual meeting in November 2026 REC-7735 (PI3Kα H1047R inhibitor): IND cleared, Phase 1/2 trial start in 2H26; a >100× mutant-selective PI3Kα H1047R inhibitor designed to improve therapeutic index by enabling deep suppression of the most common activating PI3Kα mutation while sparing wild-type PI3Kα Reduced 2026 cash operating expense guidance to 100-fold selectivity for the H1047R mutant over wild type in order to drive high, sustained target inhibition while avoiding hyperinsulinemia-driven reactivation The differentiated development candidate was delivered in 10 months and 242 compounds from first novel hit through Recursion's AI-native design platform, demonstrating the Company's ability to rapidly translate platform insights into optimized clinical candidates With the IND cleared, the Phase 1/2 ZINNIA clinical study for patients with select PIK3CA H1047R-mutant solid tumors ​will be initiated in the second half of 2026 For the rest of the portfolio, programs continue to progress as planned. Additional expected upcoming milestones across Recursion's internal pipeline: REC-1245 (RBM39): Additional Phase 1 dose escalation data expected in 2H26 REC-617 (CDK7): Early Phase 1 safety and PK combination data expected in 1H27 REC-3565 (MALT1): Early Phase 1 safety and PK monotherapy data expected in 1H27 REC-4539 (LSD1): Early Phase 1 safety and PK monotherapy data expected in 2H27 Agentic AI is compounding Recursion's advantage across Biology, Design, and ClinTech: Target Discovery Agent pairs frontier AI reasoning with Recursion's proprietary multimodal maps to surface novel drug targets, enabling scientists to mine and extract insights from proprietary maps in hours rather than weeks.